Quantum-Si incorporated (QSI)
| Market Cap | 267.04M -23.3% |
| Revenue (ttm) | 1.61M -53.0% |
| Net Income | -98.52M |
| EPS | -0.46 |
| Shares Out | 218.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,702,736 |
| Open | 1.290 |
| Previous Close | 1.280 |
| Day's Range | 1.190 - 1.410 |
| 52-Week Range | 0.690 - 3.100 |
| Beta | 3.22 |
| Analysts | Buy |
| Price Target | 2.28 (+86.89%) |
| Est. Earnings | Nov 4, 2026 |
About QSI
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer’s protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-... [Read more]
Financial Performance
In 2025, Quantum-Si incorporated's revenue was $2.44 million, a decrease of -20.34% compared to the previous year's $3.06 million. Losses were -$101.34 million, 0.33% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for QSI stock is "Buy." The 12-month stock price target is $2.28, which is an increase of 86.89% from the latest price.
News
Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro
BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecu...
Quantum-Si incorporated Slides: Investor presentation
Quantum-Si incorporated has posted slides in relation to its latest quarterly earnings report, which was published on September 28, 2026.
Quantum-Si incorporated Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is prioritizing completion and commercial launch of its Proteus platform in Q2 2027, with a focus on improving manufacturing consistency and expanding amino acid detection to 20. Road shows and organizational changes support market readiness, while key milestones include technology integration and early customer engagement.
Quantum-Si demonstrates sequencing with detection of 18 amino acids
Quantum-Si (QSI) announced that it has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus instruments. The company continues to expect to demo...
Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™
BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecu...
Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities
BRANFORD, Conn., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through si...
Sylvia Jablonski on Memory, Photonics "Fuel" Powering AI, ETFs Tied to Trade
Nvidia (NVDA) showed the AI trade remains very much alive, says Sylvia Jablonski, along with how important everything that energizes AI really is. She talks about how memory and photonics "fuel the en...
Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
BRANFORD, Conn., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through sin...
Quantum-Si price target lowered to $1.90 from $2.50 at Alliance Global
Alliance Global analyst Scott Henry lowered the firm’s price target on Quantum-Si (QSI) to $1.90 from $2.50 and keeps a Buy rating on the shares following the Q2 report. The…
Quantum-Si incorporated Earnings Call Transcript: Q2 2026
Proteus launch is delayed to Q2 2027 to add a design cycle, improving manufacturing and product readiness. Operating expenses are being reduced by 20% headcount, with $12M in annual savings expected. Cash runway extends into Q4 2028, and full-year guidance is reiterated.
Quantum-Si incorporated Earnings release: Q2 2026
Quantum-Si incorporated released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Quantum-Si incorporated Quarterly report: Q2 2026
Quantum-Si incorporated has published its Q2 2026 quarterly earnings report on August 13, 2026.
Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update
Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein se...
Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026
BRANFORD, Conn., July 27, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through sin...
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Quantum-Si announces partnership with Cell Signaling Technology
Quantum-Si (QSI) announced a partnership with Cell Signaling Technology to advance and validate next-generation protein sequencing and analysis of post-translational modifications on the Proteu single...
Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™.
Quantum-Si announces expansion of Proteus Roadshow
Quantum-Si (QSI) announced the expansion of a roadshow designed to accelerate the education of the market on its Proteus platform and applications for protein sequencing. The roadshow includes informa...
Quantum-Si Announces the Expansion of the Proteus™ Roadshow
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Expansion of the Proteus™ Roadshow.
Quantum-Si incorporated Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Proteus, a next-generation protein sequencing platform, is set for late 2024 launch with a scalable roadmap, enhanced PTM detection, and a $425,000 price point. Ongoing upgrades will be delivered via software and consumables, supported by strong cash reserves and a global commercialization strategy.
Quantum-Si incorporated Earnings Call Transcript: Q1 2026
Q1 2026 saw modest revenue and disciplined spending as focus shifted to the Proteus platform, which achieved key development milestones and strong early customer interest. Cash reserves remain robust, supporting operations into 2028, with commercial launch of Proteus on track for year-end.
Quantum-Si incorporated Earnings release: Q1 2026
Quantum-Si incorporated released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Quantum-Si incorporated Quarterly report: Q1 2026
Quantum-Si incorporated has published its Q1 2026 quarterly earnings report on May 7, 2026.
Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones.
Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference.